Amylyx Pharmaceuticals (AMLX) Inventory Average (2022 - 2023)
Amylyx Pharmaceuticals (AMLX) posted quarterly Inventory Average of $35.3 million for Q4 2023, up 584.25% year-over-year from $5.2 million in Q4 2022, and up 23.53% quarter-over-quarter from $28.6 million in Q3 2023.
Amylyx Pharmaceuticals (AMLX) Inventory Average (2022 - 2023) Analysis & Trends
Amylyx Pharmaceuticals' Inventory Average history runs 2 years deep, the most recent figure standing at $35.3 million for Q4 2023.
- In Q4 2023, Inventory Average rose 584.25% year-over-year to $35.3 million; the TTM figure through Dec 2023 stood at $35.3 million (up 584.25% YoY), while the FY2023 annual figure was $24.0 million, changed N/A from the prior year.
- Inventory Average for Q4 2023 stood at $35.3 million, up from $28.6 million in the prior quarter.
- The five-year high for Inventory Average was $35.3 million in Q4 2023, with the low at $5.2 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.71 Bn | 42.75 Bn | - | 1.41 Bn |
| 2 | Teva Pharmaceutical Industries | 43.11 Bn | 39.45 Bn | 2.15 Bn | 3.20 Bn |
| 3 | Zoetis | 31.62 Bn | 29.94 Bn | 1.05 Bn | 2.56 Bn |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | 8.99 Bn |
| 5 | United Therapeutics | 22.33 Bn | 19.67 Bn | 683.80 Mn | 186.05 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 3.93 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 84.35 Mn |
| 8 | Elanco Animal Health | 12.10 Bn | 11.57 Bn | 798.00 Mn | 1.74 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 824.00 Mn |
| 10 | Amylyx Pharmaceuticals | 4.28 Bn | 4.28 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 35.35 Mn |
| Sep 30, 2023 | 28.62 Mn |
| Jun 30, 2023 | 18.97 Mn |
| Mar 31, 2023 | 11.42 Mn |
| Dec 31, 2022 | 5.17 Mn |